Cargando…

Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain

OBJECTIVE: Assessment of analgesic effectiveness, safety, and tolerability of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTcP) in routine clinical practice. METHODS: A prospective, open-label, noninterventional study (4-week observation period, 3 month follow-up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueberall, Michael A, Lorenzl, Stefan, Lux, Eberhard A, Voltz, Raymond, Perelman, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993561/ https://www.ncbi.nlm.nih.gov/pubmed/27574463 http://dx.doi.org/10.2147/JPR.S106177

Ejemplares similares

Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer
por: Pointreau, Yoann, et al.
Publicado: (2020)

Management of predictable pain using fentanyl pectin nasal spray in patients undergoing radiotherapy
por: Bell, Brent C, et al.
Publicado: (2013)

Fentanyl Sublingual Spray for Breakthrough Pain in Cancer Patients
por: Zeppetella, Giovambattista
Publicado: (2013)

Single-dose fentanyl sublingual spray for breakthrough cancer pain
por: Taylor, Donald R
Publicado: (2013)

Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2019)

Role of intranasal fentanyl in breakthrough pain management in cancer patients
por: Leppert, Wojciech
Publicado: (2010)

Considerations in selecting rapid-onset opioids for the management of breakthrough pain
por: Perelman, Michael, et al.
Publicado: (2013)

Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2021)

Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness
por: Janssen, Daisy J.A., et al.
Publicado: (2019)

Intranasal Fentanyl for Intervention-Associated Breakthrough Pain After Cardiac Surgery
por: Valtola, Antti, et al.
Publicado: (2021)

Comparison of analgesia, adverse effects, and quality of life in cancer patients during treatment of procedural pain with intravenous morphine, fentanyl nasal spray, and fentanyl buccal tablets
por: Piotrowska, Wieslawa, et al.
Publicado: (2019)

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain
por: Prommer, Eric, et al.
Publicado: (2012)

Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
por: Darbà, Josep, et al.
Publicado: (2013)

Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment
por: Cortesi, Paolo Angelo, et al.
Publicado: (2017)

Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
por: Guitart, Jordi, et al.
Publicado: (2018)

Safety and Efficacy of Oral Transmucosal Fentanyl Citrate Compared to Morphine Sulphate Immediate Release Tablet in Management of Breakthrough Cancer Pain
por: Bhatnagar, Sushma, et al.
Publicado: (2014)

Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
por: Guitart, Jordi, et al.
Publicado: (2018)

Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis
por: Janknegt, Robert, et al.
Publicado: (2018)

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain
por: Mercadante, S, et al.
Publicado: (2007)

Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain: Pharmacokinetics of Buccal Mucosa Delivery and Clinical Efficacy
por: Darwish, Mona, et al.
Publicado: (2010)

Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets
por: Guitart, Jordi, et al.
Publicado: (2019)

A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management
por: Howarth, Peter H.
Publicado: (1995)

An Evaluation of Total Disintegration Time for Three Different Doses of Sublingual Fentanyl Tablets in Patients with Breakthrough Pain
por: Nalamachu, Srinivas
Publicado: (2013)

Physicians Experience with and Expectations of the Safety and Tolerability of WHO-Step III Opioids for Chronic (Low) Back Pain: Post Hoc Analysis of Data from a German Cross-Sectional Physician Survey
por: Ueberall, Michael A., et al.
Publicado: (2015)

Liposomal Nasal Spray versus Guideline-Recommended Steroid Nasal Spray in Patients with Chronic Rhinosinusitis: A Comparison of Tolerability and Quality of Life
por: Eitenmüller, Anna, et al.
Publicado: (2014)

Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis
por: Mösges, Ralph, et al.
Publicado: (1995)

A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet
por: Freye, Enno
Publicado: (2008)

Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study
por: Rauck, R., et al.
Publicado: (2010)

Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS
por: Masel, Eva Katharina, et al.
Publicado: (2017)

Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study
por: Guitart, Jordi, et al.
Publicado: (2017)

Tolerability and effects on quality of life of liposomal nasal spray treatment compared to nasal ointment containing dexpanthenol or isotonic NaCl spray in patients with rhinitis sicca
por: Hahn, C., et al.
Publicado: (2013)

Noninterventional Open-Label Trial Investigating the Efficacy and Safety of Ectoine Containing Nasal Spray in Comparison with Beclomethasone Nasal Spray in Patients with Allergic Rhinitis
por: Sonnemann, Uwe, et al.
Publicado: (2014)

On the Use and the Abuse of Nasal Sprays
por: Roy, Dunbar
Publicado: (1901)

Allergic Contact Dermatitis to Fentanyl TTS with Good Tolerance to Systemic Fentanyl
por: Rojas-Pérez-Ezquerra, Patricia, et al.
Publicado: (2019)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Treatment of Allergic Rhinitis with Ectoine Containing Nasal Spray and Eye Drops in Comparison with Azelastine Containing Nasal Spray and Eye Drops or with Cromoglycic Acid Containing Nasal Spray
por: Werkhäuser, Nina, et al.
Publicado: (2014)

Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations
por: Ueberall, Michael A, et al.
Publicado: (2016)

Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold
por: Bichiri, Diana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8leqe8c1cmp3p6g4istqmjrtvd